福島県立医科大学眼科学講座

メニュー

業績と研究

ホーム > 業績と研究 > 研究業績

研究業績

福島医大眼科学講座では黄斑網膜硝子体疾患、眼腫瘍、眼形成、眼窩疾患、小児眼科、斜視弱視、コンタクトレンズ、角膜疾患、緑内障、神経眼科の分野を中心に、広く情報発信をしています。

最新学会発表

第129回日本眼科学会（東京）2025年4月

  • 向井亮.
  • 新生血管型加齢黄斑変性おける脈絡膜透過性亢進とファリシマブ治療後の臨床経過との関連について.
  • 森隆史.
  • 小児の眼底検査をするために（鎮静・固定など）.
  • 本庄純一郎.
  • 7年間経過を追跡できた新生血管型加齢黄斑変性における線維化の解析.
  • 土屋雄一郎.
  • 初回生検時、硝子体内ウイルスが陽性であった眼内悪性リンパ腫の1例.
  • 錫谷学.
  • Fuchs角膜内皮ジストロフィの前房水中補体活性化産物変化.

新着掲載論文

『Exploring the comparative regressive effects of aflibercept and faricimab on pigment epithelial detachment.』
Mukai R, Honjo J, Tanaka K, Sekiryu T.  BMC Ophthalmol. 2024;24:393.

『Efficacy of 3% diquafosol long-acting eye drops in dry eye patients treated for three months. 』
Maehara H, Mukai R, Iitaka Y, Sekiryu T..Jpn J Ophthalmol. 2024;68:338-345.

『One-year outcomes and safety assessment of faricimab in treatment-naïve patients with neovascular age-related macular degeneration in Japan.』
Mukai R, Kataoka K, Tanaka K, Miyara Y, Maruko I, Nakayama M, Watanabe Y, Yamamoto A, Wakatsuki Y, Onoe H, Wakugawa S, Terao N, Hasegawa T, Kawai M, Maruko R, Itagaki K, Honjo J, Okada AA, Mori R, Koizumi H, Iida T, Sekiryu T. Sci Rep. 2024;14:11681.

『Association between the arm-to-choroidal circulation time and clinical profile in patients with polypoidal choroidal vasculopathy.』
Mukai R, Itagaki K, Honjyo J, Tanaka K, Norikawa K, Sekiryu T. Jpn J Ophthalmol. 2024;68:211-215.

『Intraocular pressure changes during intravitreal aflibercept injection based on treat-and-extend regimen in Japanese patients with neovascular age-related macular degeneration and glaucoma. 』
Honjo J, Mukai R, Itagaki K, Tanaka K, Norikawa K, Kato Y, Kasai A, Sugano Y, Sekiryu T. Jpn J Ophthalmol. 2024;68:91-95.

『Complement activation products in tears of dry eye and meibomian gland dysfunction. 』
Maehara H, Norikawa K, Tanaka K, Kato Y, Kasai A, Mukai R, Omori T, Machida T, Sekine H, Sekiryu T. Sci Rep. 2024;14:43.

眼科業績 2024年-2025年

原著
1. Maehara H, Ueno Y, Yamaguchi T, Kitaguchi Y, Miyazaki D, Nejima R, Inomata T, Kato N, Chikama TI, Ominato J, Yunoki T, Tsubota K, Oda M, Suzutani M, Sekiryu T, Oshika T.　Artificial intelligence support improves diagnosis accuracy in anterior segment eye diseases. Sci Rep. 2025;15:5117.
2. Maehara H, Ueno Y, Yamaguchi T, Kitaguchi Y, Miyazaki D, Nejima R, Inomata T, Kato N, Chikama TI, Ominato J, Yunoki T, Tsubota K, Oda M, Suzutani M, Sekiryu T, Oshika T.     The importance of clinical experience in AI-assisted corneal diagnosis: verification using intentional AI misleading. Sci Rep. 2025;15:1462.
3. Iimori H, Nishikawa N, Nishina S, Yoshida T, Mori T, Hieda O, Hikoya A, Komori M, Hayashi S, Negishi T, Goseki T, Sugiyama Y, Kimura A, Morimoto T, Shimizu Y, Shimizu T, Yokoyama Y, Suzuki H, Suzuki S, Azuma N, Sato M. Impact of prolonged digital device use on acquired comitant esotropia: ACE-DD study 2. Jpn J Ophthalmol. 2025;69:166-173.
4. Matsuura K, Sasaki SI, Inoue H, Mori T, Sugihara K. Survey: Practice patterns of intravitreal injection in Japan. Asia Pac J Ophthalmol. 2025;24:100169.
5. Mukai R, Honjo J, Tanaka K, Sekiryu T. Exploring the comparative regressive effects of aflibercept and faricimab on pigment epithelial detachment. BMC Ophthalmol. 2024;24:393.
6. Maehara H, Mukai R, Iitaka Y, Sekiryu T. Efficacy of 3% diquafosol long-acting eye drops in dry eye patients treated for three months. Jpn J Ophthalmol. 2024;68:338-345.
7. Mukai R, Kataoka K, Tanaka K, Miyara Y, Maruko I, Nakayama M, Watanabe Y, Yamamoto A, Wakatsuki Y, Onoe H, Wakugawa S, Terao N, Hasegawa T, Kawai M, Maruko R, Itagaki K, Honjo J, Okada AA, Mori R, Koizumi H, Iida T, Sekiryu T. One-year outcomes and safety assessment of faricimab in treatment-naïve patients with neovascular age-related macular degeneration in Japan. Sci Rep. 2024;14:11681.
8. Mukai R, Itagaki K, Honjyo J, Tanaka K, Norikawa K, Sekiryu T. Association between the arm-to-choroidal circulation time and clinical profile in patients with polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 2024;68:211-215.
9. Honjo J, Mukai R, Itagaki K, Tanaka K, Norikawa K, Kato Y, Kasai A, Sugano Y, Sekiryu T. Intraocular pressure changes during intravitreal aflibercept injection based on treat-and-extend regimen in Japanese patients with neovascular age-related macular degeneration and glaucoma. Jpn J Ophthalmol. 2024;68:91-95.
10. Maehara H, Norikawa K, Tanaka K, Kato Y, Kasai A, Mukai R, Omori T, Machida T, Sekine H, Sekiryu T. Complement activation products in tears of dry eye and meibomian gland dysfunction. Sci Rep. 2024;14:43.
11. Muto T, Kawaguchi S, Kusuda S, Misu K, Sakamoto M, Machida S, Imaizumi S, Sekiryu T. Early Changes in Ocular Biomarkers in Patients with Vogt-Koyanagi-Harada Disease After Pulse Steroid Therapy. Ophthalmologica. 2024;21:1-14.
12. Muto T, Sakamoto M, Machida S, Imaizumi S, Sekiryu T. Effect of Vitreous Reflux after Intravitreal Aflibercept Injection for Macular Edema with Branch Retinal Vein Occlusion: A Real-World Study. J Ophthalmol. 2024;7645490.
13. Muto T, Sakamoto M, Kusuda S, Haruyama Y, Machida S, Imaizumi S, Sekiryu T. Effect of the COVID-19 pandemic on Vogt-Koyanagi-Harada disease. Sci Rep. 2024;14:13211.
14. Sugimoto K, Murakami T, Ojima A, Sekiryu T. Comparison of clinical findings and subjective symptoms in a case of multiple evanescent white dot syndrome (MEWDS): A case report from a patient’s perspective. J Gen Fam Med. 2024;25:154-157.
15. Nishikawa N, Iimori H, Kinouchi R, Nishina S, Yoshida T, Hikoya A, Komori M, Hieda O, Goseki T, Mori T, Morimoto T, Negishi T, Shimizu T, Shimizu Y, Hayashi S, Sugiyama Y, Yokoyama Y, Kimura A, Suzuki H, Suzuki S, Azuma N, Sato M. Factors affecting outcome of acquired comitant esotropia with restricted use of digital devices: ACEDD Study 3. BMJ Open Ophthalmol. 2024;9:e001713.
16. Oshika T, Nishina S, Unoki N, Miyagi M, Nomura K, Mori T, Matsuki N, Endo T, Kurosaka D, Negishi K, Yoshida S, Nagamoto T. Ten-year outcomes of congenital cataract surgery performed within the first six months of life. J Cataract Refract Surg. 2024;50:707-712.
17. Teo KYC, Park KH, Ngah NF, Chen SJ, Ruamviboonsuk P, Mori R, Kondo N, Lee WK, Rajagopalan R, Obata R, Wong IYH, Chee C, Terasaki H, Sekiryu T, Chen SC, Yanagi Y, Honda S, Lai TYY, Cheung CMG. Six-Year Outcomes in Subjects with Polypoidal Choroidal Vasculopathy in the EVEREST II Study. Ophthalmol Ther. 2024;13:935-954.
18. Inoda S, Takahashi H, Maruyama-Inoue M, Ikeda S, Sekiryu T, Itagaki K, Matsumoto H, Mukai R, Nagai Y, Ohnaka M, Kusuhara S, Miki A, Okada AA, Nakayama M, Nishiguchi KM, Takeuchi J, Mori R, Tanaka K, Honda S, Kohno T, Koizumi H, Miyara Y, Inoue Y, Takana H, Iida T, Maruko I, Hayashi A, Ueda-Consolvo T, Yanagi Y. Incidence and risk factors of intraocular inflammation after brolucizumab treatment in Japan: A Multicenter Age-Related Macular Degeneration Study. Retina. 2024;44:714-722.
19. Kataoka K, Itagaki K, Hashiya N, Wakugawa S, Tanaka K, Nakayama M, Yamamoto A, Mukai R, Honjyo J, Maruko I, Kawai M, Miyara Y, Terao N, Wakatsuki Y, Onoe H, Mori R, Koizumi H, Sekiryu T, Iida T, Okada AA; for Japan AMD Research Consortium (JARC). Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2024;262:43-51.
20. Muto T, Sakamoto M, Imaizumi S, Kamoi K. Reactivation of previously controlled Vogt-Koyanagi-Harada disease more than 46 years following COVID-19 vaccination: a case study.   J Int Med Res. 2024;52:3000605231221081.
21. Stahl A, Nakanishi H, Lepore D, Wu WC, Azuma N, Jacas C, Vitti R, Athanikar A, Chu K, Iveli P, Zhao F, Leal S, Schlief S, Schmelter T, Miller T, Köfüncü E, Fielder A; FIREFLEYE next Study Group. Intravitreal Aflibercept vs Laser Therapy for Retinopathy of Prematurity: Two-Year Efficacy and Safety Outcomes in the Nonrandomized Controlled Trial FIREFLEYE next. JAMA Netw Open. 2024;7:e248383.
22. Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, Guymer R, Heier JS, Holz FG, Iida T, Ives JA, Lim JI, Lin H, Michels S, Quezada Ruiz C, Schmidt-Erfurth U, Silverman D, Singh R, Swaminathan B, Willis JR, Tadayoni R; TENAYA and LUCERNE Investigators. TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2. Ophthalmology. 2024;131:914-926.
23. 松野希望, 赤井田あかね, 森隆史, 笠井彩香, 石龍鉄樹. 小児のロービジョンにおける低コントラスト視力と遮光眼鏡. 眼科臨床紀要2024;17:479-483.

お問い合わせcontact

福島県立医科大学眼科学講座
〒960-1247 福島県福島市光が丘1番地
TEL：024-547-1111（代表）
E-mail：
※メールでは個別の健康相談には応じておりませんのでご了承ください